Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The interaction between the gut microbiota and luminal dietary starch is a fundamental metabolic process that significantly influences human health. Dietary starch that escapes enzymatic digestion in the small intestine, known as resistant starch, reaches the colon where it serves as a primary substrate for fermentation by specific anaerobic bacteria, such as Ruminococcus bromii and Bifidobacterium species (Bird et al., 2010; Walker et al., 2011). This fermentation produces short-chain fatty acids (SCFAs), including acetate, propionate, and butyrate, which provide energy for colonocytes and function as systemic signaling molecules (Topping & Clifton, 2001). These metabolites play a crucial role in maintaining gut barrier integrity, modulating the immune system, and improving insulin sensitivity through the activation of host receptors like GPR41 and GPR43 (Koh et al., 2016). Dysregulation of this system is associated with various metabolic and inflammatory diseases, including obesity and inflammatory bowel disease. While not a single molecular target, this biological axis is modulated by drugs like acarbose, which increases the delivery of starch to the colon to promote beneficial microbial activity and improve glycemic control (Gu et al., 2017). Consequently, this system is a major focus for the development of prebiotic and probiotic therapies aimed at restoring metabolic homeostasis.
The interaction involves the microbial fermentation of undigested dietary starch (resistant starch) in the large intestine, primarily by specialized bacteria like Ruminococcus bromii. This process generates short-chain fatty acids (SCFAs) such as butyrate, propionate, and acetate, which act as signaling molecules by binding to G protein-coupled receptors (GPR41 and GPR43) and inhibiting histone deacetylases (HDACs) to regulate host inflammation and glucose metabolism (Koh et al., 2016; Walker et al., 2011).
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Gut microbiota and luminal dietary starch.